Ulf Eriksson


Affiliation: Karolinska Institutet
Country: Sweden


  1. Eriksson U, Falkevall A. Visualizing Fatty Acid Flux. Cell Metab. 2018;27:1161-1162 pubmed publisher
    ..This allows for detailed analyses of this clearly complex process. ..
  2. Lewandowski S, Fredriksson L, Lawrence D, Eriksson U. Pharmacological targeting of the PDGF-CC signaling pathway for blood-brain barrier restoration in neurological disorders. Pharmacol Ther. 2016;167:108-119 pubmed publisher
    ..In summary: inhibition of PDGF-CC signaling can be protective for immediate injury and decrease the long-term neurodegenerative consequences. ..
  3. Lewandowski S, Nilsson I, Fredriksson L, Lönnerberg P, Muhl L, Zeitelhofer M, et al. Presymptomatic activation of the PDGF-CC pathway accelerates onset of ALS neurodegeneration. Acta Neuropathol. 2016;131:453-64 pubmed publisher
    ..We conclude that PDGF-CC-induced BSCB dysfunction can contribute to timing of ALS onset, allow insight into disease origins and development of targeted novel therapies. ..
  4. Muhl L, Moessinger C, Adzemovic M, Dijkstra M, Nilsson I, Zeitelhofer M, et al. Expression of vascular endothelial growth factor (VEGF)-B and its receptor (VEGFR1) in murine heart, lung and kidney. Cell Tissue Res. 2016;365:51-63 pubmed publisher
  5. Falkevall A, Mehlem A, Palombo I, Heller Sahlgren B, Ebarasi L, He L, et al. Reducing VEGF-B Signaling Ameliorates Renal Lipotoxicity and Protects against Diabetic Kidney Disease. Cell Metab. 2017;25:713-726 pubmed publisher
    ..Further, we show that elevated VEGF-B levels are found in patients with DKD, suggesting that VEGF-B antagonism represents a novel approach to treat DKD. ..